Qualthera

Qualthera is a Salt Lake City-based biotechnology company dedicated to advancing precision oncology through its proprietary functional screening platform, Qual-Screen. The company's technology enables the rapid identification of optimal therapeutic combinations and the discovery of novel small molecule inhibitors for challenging targets like KRAS. By leveraging patient-derived models and high-throughput analysis, Qualthera aims to deliver personalized treatment strategies for patients with refractory solid tumors. Their lead programs focus on next-generation KRAS inhibitors designed to overcome resistance mechanisms seen with first-generation therapies.